ROIV

MKT CAP:$20B

Roivant Sciences Ltd.

Market Cap

$20B

Healthcare·Biotechnology·🇬🇧 United Kingdom·NASDAQ

Healthcare·Biotechnology·🇬🇧·NASDAQ

Stock Price

$27.41+$5.48 (+24.99%)

Apr 24, 2026

Company Details

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell dise...

CEO

Matthew Gline

IPO Date

Dec 8, 2020

Website

roivant.com

Key Metrics TTM

Revenue

$2M

— YoY

Net Income

-$114M

EPS (Diluted)

-$0.17

Free Cash Flow

-$194M

Revenue / Share

$0.00

Gross Margin

92.9%

Operating Margin

-19492.9%

Net Margin

-7225.9%

FCF Margin

-12317.8%

P/S

12511.1x

P/E

—

Earnings Reports

FY 2025

Nov 10, 2025

$2MEPS -$0.17

Q2 2025

Nov 10, 2025

$2MEPS -$0.17

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 25	$2M	$1M	-$306M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 23	-$210M	-$211M
Q2 25	-$186M	-$194M

Capital Expenditures

Quarter	CapEx
Q3 23	$355.0K
Q2 25	$8M

CapEx

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 23	$54M	—
Q2 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A
Q2 25	$165M	$143M

Revenue Segments

Quarter	Reportable Segment
Q2 25	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q3 22	$1.5B	$0	$1.5B
Q4 22	$1.7B	$0	$1.7B
Q1 23	$1.4B	$0	$1.4B
Q2 23	$1.4B	$0	$1.4B
Q3 23	$6.7B	$0	$6.7B
Q4 23	$6.5B	$5M	$6.5B
Q1 24	$5.7B	$0	$5.7B
Q2 24	$2.0B	$3.4B	$5.4B
Q3 24	$2.0B	$3.2B	$5.1B
Q4 24	$2.7B	$2.2B	$4.9B
Q1 25	$1.2B	$3.3B	$4.5B
Q2 25	$1.2B	$3.1B	$4.4B
Q3 25	$1.5B	$3.1B	$4.5B

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 25	681M	—	—

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 25	$2.1K	750

Revenue / Employee